辰欣药业股份有限公司 信息披露暂缓与豁免管理制度 （2025年10月） 第一章 总则 第一条 为规范辰欣药业股份有限公司（以下简称"公司"）信息披露暂缓 与豁免行为，确保本公司和其他信息披露义务人依法合规履行信息披露义务， 保护投资者的合法权益，根据《中华人民共和国证券法》《上海证券交易所股 票上市规则》（以下简称"《股票上市规则》"）、《上市公司信息披露管理 办法》《上市公司信息披露暂缓与豁免管理规定》及《辰欣药业股份有限公司 章程》（以下简称"公司章程"），特制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会和上海证券交易所规定或者要求 披露的内容，适用本制度。 第三条 公司应当披露的信息存在《股票上市规则》或上海证券交易所其他 相关规则中规定的暂缓、豁免披露情形的，由公司自行审慎判断，可依照本制 度经公司内部审批后暂缓、豁免披露，并接受上海证券交易所对有关信息披露 暂缓、豁免事项的事后监管。 第二章 暂缓、豁免披露信息的范围 第四条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避 ...

辰欣药业股份有限公司 董事会提名委员会工作细则 （2025 年 10 月修订） 1 / 6 第一章 总则 1.1 为规范辰欣药业股份有限公司（以下简称"公司"）董事会组成以及 高级管理人员的聘任，确保董事会的有效监督，进一步完善公司法人治理结构， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《辰欣药业股份 有限公司章程》（以下简称"《公司章程》"）及其他有关规定，制订本工作细 则。 第二章 人员组成及任职 2.1 提名委员会成员由三名董事组成，其中独立董事应当过半数并担任召 集人。 提名委员会委员由公司董事长、二分之一以上独立董事或者三分之一以上全 体董事提名，由董事会过半数选举产生。 2.2 提名委员会设主任委员（召集人）一名，由独立董事委员担任，负责 主持委员会工作；主任委员由董事长提名，由董事会委任，如果主任委员不能履 行职务或不履行职务的，由董事会另行委任一名独立董事作为主任委员。 董事会办公室负责提名委员会日常工作联络和会议组织等工作。 （一）提名或者任免董事； 2.3 提名委员会任期三年，与同届董事会任期一致，委员任期届满，连选 可以连任。如果委员任期内不再担任董事资格，自动失去委员资 ...

第一条 为提高辰欣药业股份有限公司（以下简称"公司"）的规范运作水 平，增强信息披露的真实性、准确性、完整性、及时性，加大对年报信息披露 责任人的问责力度，增强年报信息披露的质量和透明度，保护投资者合法权益， 根据《中华人民共和国证券法》《企业会计准则》《上市公司信息披露管理办 法》《上市公司治理准则》《上海证券交易所股票上市规则》等法律、法规、 规范性文件以及《辰欣药业股份有限公司章程》的有关规定，结合公司实际情 况，制定本制度。 第二条 本制度所称"年报信息披露重大差错"，是指足以影响年报使用人 对公司财务状况、经营成果和现金流量以及年报的其他内容做出正确判断的重 大差错，包括但不限于年报内容不真实、不准确、不完整和虚假记载、误导性 陈述或者重大遗漏。 第三条 本制度所指"责任追究制度"是指年报信息披露工作中有关人员不 履行或者不正确履行职责、义务或其他个人原因，导致年报信息存在虚假记载 和重大差错，对公司造成重大经济损失或者不良社会影响时的追究与处理制度。 第四条 本制度适用于公司董事、高级管理人员、各职能部门负责人、公司 所属各子公司、分公司负责人、控股股东及实际控制人以及与年报信息披露有 关的其他人 ...

Core Viewpoint - Chenxin Pharmaceutical has shown significant stock price appreciation this year, with a year-to-date increase of 85.19% and notable recent trading activity, indicating strong market interest and potential investment opportunities [1][2]. Group 1: Stock Performance - As of October 23, Chenxin Pharmaceutical's stock price reached 24.69 CNY per share, with a trading volume of 5.84 billion CNY and a turnover rate of 5.28%, resulting in a total market capitalization of 111.78 billion CNY [1]. - The stock has experienced a 16.74% increase over the last five trading days, a 17.45% increase over the last 20 days, and a 20.78% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on October 17, where it recorded a net purchase of 1.29 billion CNY [1]. Group 2: Company Overview - Chenxin Pharmaceutical, established on November 6, 1998, and listed on September 29, 2017, is located in Jining, Shandong Province, and specializes in the research, development, and production of chemical drug formulations [2]. - The company's revenue composition includes: large-volume injections (42.66%), small-volume injections (29.80%), oral solid preparations (13.98%), and other formulations [2]. - As of June 30, the number of shareholders increased by 68.07% to 35,900, while the average circulating shares per person decreased by 40.50% to 12,602 shares [2]. Group 3: Financial Performance - For the first half of 2025, Chenxin Pharmaceutical reported a revenue of 1.74 billion CNY, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million CNY, down 15.23% year-on-year [2]. - The company has distributed a total of 1.197 billion CNY in dividends since its A-share listing, with 633 million CNY distributed over the past three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, increasing its holdings by 196.89 million shares [3].

Group 1 - Major focus stocks include Dayou Energy, which opened up 8.08% after 13 consecutive days of gains [1] - Bluefeng Biochemical, investing in the new energy sector, opened down 5.85% after 17 consecutive days of gains [1] - Retail stock Guoguang Chain opened up 0.22% after 8 consecutive days of gains [1] Group 2 - Low-priced stock Haiou Zhugong opened down 4.08% after 10 consecutive days of gains [1] - Maohua Shihua opened down 4.62% after 2 consecutive days of gains [1] - Robotics concept stock Ruineng Technology opened down 8.24% after 5 consecutive days of gains [1] Group 3 - Deep Earth Economy concept stock Huanghe Xuanfeng opened up 5.05% after 7 consecutive days of gains [1] - Shihua Machinery opened at the daily limit after 3 consecutive days of gains [1] - Antiviral concept stock Yatai Pharmaceutical opened up 0.26% after 7 consecutive days of gains [1] Group 4 - Chenxin Pharmaceutical opened flat after 4 consecutive days of gains [1] - Mergers and acquisitions stock Yingxin Development opened at the daily limit after 3 consecutive days of gains [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.32% on October 22, with Dize Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Xiangdi Pharmaceutical (301211) with a closing price of 14.99, up 14.25% [1] - Duorui Pharmaceutical (301075) at 58.62, up 10.21% [1] - Guangji Pharmaceutical (000952) at 7.77, up 10.06% [1] - Hasi Lian (002900) at 14.61, up 10.02% [1] - Yatai Pharmaceutical (002370) at 7.70, up 10.00% [1] - Dize Pharmaceutical (688192) was the biggest loser, closing at 60.11, down 6.20% [2] - Other significant decliners included: - Kangzhiyue Pharmaceutical (300086) down 5.90% [2] - Puluo Pharmaceutical (000739) down 5.41% [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 185 million yuan from institutional investors, while retail investors experienced a net inflow of 41.4 million yuan [2] - However, speculative funds recorded a net outflow of 227 million yuan [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Yatai Pharmaceutical (002370) with a net inflow of 2.38 billion yuan from institutional investors, but a net outflow of 95.28 million yuan from speculative funds [3] - Anglikang (002940) had a net inflow of 182 million yuan from institutional investors, with a net outflow of 97.14 million yuan from speculative funds [3] - Hasi Lian (002900) recorded a net inflow of 117 million yuan from institutional investors, but a significant net outflow of 59.36 million yuan from speculative funds [3]

Core Viewpoint - The pharmaceutical sector has experienced significant stock price increases, with Hendi Pharmaceutical reaching a 20% limit-up, and several other companies also showing substantial gains [1] Group 1: Company Performance - Hendi Pharmaceutical's stock surged by 20%, hitting the daily limit [1] - Duori Pharmaceutical's stock rose by over 13% [1] - Other companies such as Guangji Pharmaceutical, Te Yi Pharmaceutical, Hasan Lian, and Chenxin Pharmaceutical also reached their daily limit [1]

Core Viewpoint - The A-share market continues to see an upward trend in flu-related stocks, driven by rising flu activity and concerns over a potentially severe flu season this year [1] Group 1: Stock Performance - Hendi Pharmaceutical has seen a rise of over 18% - Dori Pharmaceutical has increased by over 11% - Guangji Pharmaceutical and Te Yi Pharmaceutical have hit the 10% daily limit up - Chenxin Pharmaceutical has also increased by over 6% - Notably, Guangji Pharmaceutical has achieved two consecutive limit-up days [1] Group 2: Flu Activity and Expert Insights - The China CDC reported that flu activity in northern provinces is currently low, while southern provinces are experiencing an increase - Overall, respiratory disease incidence is showing a slow upward trend nationwide - Experts indicate that the main flu strain this year is likely to be the H3N2 subtype, which was largely absent last year, leading to lower immunity levels in the population - Many experts believe that this year's flu season may arrive earlier and result in a higher number of infections [1]

Core Viewpoint - Chenxin Pharmaceutical experienced a stock price decline of 2.01% on October 21, 2023, with a current price of 21.97 CNY per share and a total market capitalization of 9.947 billion CNY [1] Group 1: Financial Performance - Year-to-date, Chenxin Pharmaceutical's stock price has increased by 64.79%, with a 10.02% rise over the last five trading days and a 23.14% increase over the last 60 days [1] - For the first half of 2025, the company reported a revenue of 1.740 billion CNY, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million CNY, down 15.23% year-on-year [2] Group 2: Shareholder Information - As of June 30, 2025, the number of shareholders for Chenxin Pharmaceutical was 35,900, an increase of 68.07% from the previous period, with an average of 12,602 circulating shares per shareholder, a decrease of 40.50% [2] - The company has distributed a total of 1.197 billion CNY in dividends since its A-share listing, with 633 million CNY distributed over the last three years [3] Group 3: Business Overview - Chenxin Pharmaceutical, established on November 6, 1998, and listed on September 29, 2017, specializes in the research, development, and production of chemical drug formulations [2] - The company's main revenue sources include large-volume injections (42.66%), small-volume injections (29.80%), and oral solid preparations (13.98%) [2]

Core Insights - Chenxin Pharmaceutical (603367) experienced a trading halt today, with a turnover rate of 12.17% and a transaction volume of 1.248 billion yuan, showing a price fluctuation of 9.10% [1] - The stock was listed on the Shanghai Stock Exchange due to a price deviation of 11.98%, with net purchases from the Shanghai-Hong Kong Stock Connect amounting to 53.44 million yuan [1] - The stock has been on the trading list five times in the past six months, with an average price increase of 4.08% the day after being listed and an average increase of 9.19% over the following five days [1] Trading Data - The top five trading departments accounted for a total transaction volume of 374 million yuan, with a net purchase of 129 million yuan [1] - The leading buying department was the Shanghai-Hong Kong Stock Connect, with a purchase amount of 119.91 million yuan and a selling amount of 66.46 million yuan, resulting in a net purchase of 53.44 million yuan [1] - Major capital inflow for the stock today was 246 million yuan, with large single orders contributing 237 million yuan and large orders contributing 9.62 million yuan [1] Financial Performance - For the first half of the year, the company reported a revenue of 1.740 billion yuan, a year-on-year decrease of 15.97%, and a net profit of 229 million yuan, down 15.23% year-on-year [1]